CN103946202A - 包含富含氘的紫苏醇、异紫苏醇及其衍生物的药物组合物 - Google Patents

包含富含氘的紫苏醇、异紫苏醇及其衍生物的药物组合物 Download PDF

Info

Publication number
CN103946202A
CN103946202A CN201280057166.6A CN201280057166A CN103946202A CN 103946202 A CN103946202 A CN 103946202A CN 201280057166 A CN201280057166 A CN 201280057166A CN 103946202 A CN103946202 A CN 103946202A
Authority
CN
China
Prior art keywords
deuterium
enriched
alcohol
pharmaceutical composition
isoperillyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280057166.6A
Other languages
English (en)
Chinese (zh)
Inventor
T·陈
D·莱文
S·普帕利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neonc Technologies Inc
Original Assignee
Neonc Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/566,731 external-priority patent/US8916545B2/en
Application filed by Neonc Technologies Inc filed Critical Neonc Technologies Inc
Publication of CN103946202A publication Critical patent/CN103946202A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05—Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280057166.6A 2011-11-21 2012-11-21 包含富含氘的紫苏醇、异紫苏醇及其衍生物的药物组合物 Pending CN103946202A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161562105P 2011-11-21 2011-11-21
US61/562,105 2011-11-21
US13/566,731 US8916545B2 (en) 2010-08-27 2012-08-03 Pharmaceutical compositions comprising POH derivatives
US13/566,731 2012-08-03
PCT/US2012/066379 WO2013119304A2 (en) 2011-11-21 2012-11-21 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof

Publications (1)

Publication Number Publication Date
CN103946202A true CN103946202A (zh) 2014-07-23

Family

ID=48948152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280057166.6A Pending CN103946202A (zh) 2011-11-21 2012-11-21 包含富含氘的紫苏醇、异紫苏醇及其衍生物的药物组合物

Country Status (8)

Country Link
EP (1) EP2782894A4 (enExample)
JP (2) JP2015502352A (enExample)
KR (1) KR20150000469A (enExample)
CN (1) CN103946202A (enExample)
BR (1) BR112014012180A2 (enExample)
CA (1) CA2856403A1 (enExample)
HK (1) HK1201253A1 (enExample)
WO (1) WO2013119304A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936125A (zh) * 2018-02-08 2020-11-13 尼昂克技术公司 穿透血脑屏障的方法
CN116789530A (zh) * 2023-05-16 2023-09-22 杭州师范大学 一种紫苏醇酚类衍生物及其制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945335B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏胺类化合物及其制备和应用
CN104945334B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏醇衍生物及其制备和应用
CN104945333B (zh) * 2014-03-27 2018-02-02 沈阳药科大学 紫苏醇类似物及其制备和应用
CN104945336B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏酸甲酯含氮衍生物及其制备和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272441A (en) * 1980-03-13 1981-06-09 Fmc Corporation Preparation of carbamates
US20020177609A1 (en) * 2001-03-23 2002-11-28 Swindell Charles S. Fatty alcohol drug conjugates
WO2003057193A1 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Monoterpene compositions and uses thereof
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
ATE405259T1 (de) * 2004-06-23 2008-09-15 Robert F Hofmann Verwendung einer gezielten oxidativen therapeutischen formulierung bei der behandlung von verbrennungen
WO2007053189A2 (en) 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
EP2081565A2 (en) * 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
CN105078973B (zh) * 2010-08-27 2020-10-09 尼昂克技术公司 包含poh衍生物的药物组合物
CN101979378B (zh) * 2010-10-13 2012-06-27 中国科学院上海有机化学研究所 一种手性γ-内酰胺化合物的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272441A (en) * 1980-03-13 1981-06-09 Fmc Corporation Preparation of carbamates
US20020177609A1 (en) * 2001-03-23 2002-11-28 Swindell Charles S. Fatty alcohol drug conjugates
WO2003057193A1 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Monoterpene compositions and uses thereof
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAITAO等: "Synthesis of Deuterium Labeled Perillyl Alcohol and Dual C-13 and Deuterium Labeled Perillic Acid,Major Metabolites of d-Limonene", 《JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS》 *
ROGER TUNG: "The Development of Deuterium-Containing Drugs", 《INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936125A (zh) * 2018-02-08 2020-11-13 尼昂克技术公司 穿透血脑屏障的方法
US12208066B2 (en) 2018-02-08 2025-01-28 University Of Southern California Methods of permeabilizing the blood brain barrier
CN116789530A (zh) * 2023-05-16 2023-09-22 杭州师范大学 一种紫苏醇酚类衍生物及其制备方法和应用

Also Published As

Publication number Publication date
BR112014012180A2 (pt) 2017-05-30
JP2018035148A (ja) 2018-03-08
WO2013119304A3 (en) 2013-10-03
EP2782894A4 (en) 2015-03-11
KR20150000469A (ko) 2015-01-02
JP2015502352A (ja) 2015-01-22
CA2856403A1 (en) 2013-08-15
EP2782894A2 (en) 2014-10-01
WO2013119304A2 (en) 2013-08-15
HK1201253A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
CN105078973B (zh) 包含poh衍生物的药物组合物
CN105616391B (zh) 使用异紫苏醇的方法和装置
CN107613768B (zh) 包含紫苏醇衍生物的药物组合物
JP2018035148A (ja) 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物
CN107427588A (zh) 包含poh衍生物的药物组合物
US20230145207A1 (en) Pharmaceutical compositions comprising poh derivatives and methods of use
US20210244820A1 (en) Pharmaceutical compositions comprising poh derivatives
WO2019241770A1 (en) Pharmaceutical compositions comprising poh derivatives
HK1188984B (zh) 使用异紫苏醇的方法和装置

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140723

RJ01 Rejection of invention patent application after publication